Niki BioSolutions, Inc.
Research Niki BioSolutions, Inc. (NIKI) on Bullrun: market cap USD 1.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNIKI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.65M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 1.36M
- Free cash flow-USD 1.84M
Valuation Snapshot
latest market cap is USD 1.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 1.36M | -USD 1.84M | n/a | n/a | USD 3.45M | USD 3.44M | USD 23.16M |
| FY2024 | USD 0 | -USD 4.27M | -USD 1.19M | n/a | -7.8 | USD 874.24K | USD 3.35M | USD 21.13M |
| FY2023 | USD 431.38K | -USD 2.82M | -USD 7.73M | 2.4% | -6.2 | USD 2.01M | USD 3.28M | USD 24.85M |
| FY2022 | USD 1.30M | -USD 9.80M | -USD 12.51M | 6.2% | -27.5 | USD 1.88M | USD 6.85M | USD 15.71M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 1.65M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.63M | n/a | n/a | n/a |
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Niki BioSolutions, Inc.'s market cap?
Niki BioSolutions, Inc.'s market capitalization is USD 1.65M.
What does Niki BioSolutions, Inc. do?
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.